FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
FDA General

RFK Jr. reportedly Mulled Limiting Makarys Authority

HHS secretary Robert F. Kennedy Jr. reviews options to scale back the operational role of FDA commissioner Marty Makary, including the possibility of ...

latest-news-card-1
Marketing

FDA Flags AstraZenecas Farxiga TV Ad as Misleading

FDA cites a direct-to-consumer television advertisement for AstraZenecas Farxiga (dapagliflozin) tablets.

latest-news-card-1
Human Drugs

Group Seeks Stronger Pregnancy Warning on Antidepressants

Advocacy group Public Citizen petitions FDA to add new, class-wide pregnancy warnings to the labels of commonly prescribed serotonin reuptake inhibito...

latest-news-card-1
Human Drugs

NIH Grant Cuts Disrupt Hundreds of Clinical Trials: JAMA

A new JAMA research letter finds that more than 380 clinical trials supported by the NIH lost funding this year affecting about 1 in 30 a...

latest-news-card-1
Human Drugs

Aseptic Breakdowns at Sanofis Fill-Finish Plant: FDA

FDA posts a Form 483 that cites significant lapses in aseptic manufacturing practices at Sanofis sterile drug-product facility in Anagni, Italy.

latest-news-card-1
Human Drugs

FDA Generic User Fee Negotiations Offer Proposals

FDA and generic drug manufacturers kick off formal negotiations on the next cycle of the Generic Drug User Fee Amendments during a recent meeting at t...

latest-news-card-1
Human Drugs

Hims & Hers Names Ex-FDAer Autor as Chief Policy Officer

Hims & Hers Health appoints former FDA Global Regulatory Operations and Policy deputy commissioner Deb Autor as its first chief policy officer.

latest-news-card-1
Biologics

Promising Ziihera Data in Gastric Cancer Trial

Zymeworks reports that its HER2-targeted bispecific antibody Ziihera (zanidatamab-hrii) significantly improved outcomes for patients with HER2-positiv...

latest-news-card-1
Human Drugs

Former FDA CMC Reviewer Joins Law Firm

Former CDER chemistry, manufacturing and controls (CMC) reviewer Fabiola Cervantes-Gomez joins Hyman, Phelps & McNamaras as a CMC regulatory expert.

latest-news-card-1
Human Drugs

BMS, J&J Halt Phase 3 Librexia Trial After Futility Review

Bristol Myers Squibb (BMS) and Johnson & Johnson stop their Phase 3 Librexia ACS trial of the investigational anticoagulant milvexian after an indepen...